Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 23, 2013Clinical Pharmacology & TherapeuticsOpen Access

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMichael A. ProvincePennington Biomedical Research CenterMGMatthew P. GoetzMayo ClinicHBHiltrud BrauchGerman Cancer Research Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Province et al. (2013) studied this question.

synapsesocial.com/papers/6ab0c1d497f7c5d265add894https://doi.org/10.1038/clpt.2013.186
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Differential patterns of allelic loss in estrogen receptor‐positive infiltrating lobular and ductal breast cancer2008 · 31 citations
  2. 2Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System2007 · 895 citations
  3. 3Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial2010 · 86 citations
  4. 4CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial2012 · 340 citations
  5. 5CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients2012 · 258 citations